Fidelity National Financial Inc. Takes $20.23 Million Position in Abbott Laboratories $ABT

Key Points

• Fidelity National Financial opened a $20.23 million position in Abbott Laboratories, purchasing 223,000 shares; institutional investors collectively own 75.18% of the company.
• Analyst sentiment remains favorable, with Abbott receiving a “Moderate Buy” consensus rating and an average price target of $119.50, although targets range from $102 to $135.
• Abbott’s latest quarter beat expectations, with revenue up 13% year over year, while new diabetes-monitoring and heart-care device approvals support future growth. The company also pays a $0.63 quarterly dividend, yielding about 2.2%.

Fidelity National Financial Inc. bought a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 223,000 shares of the healthcare product maker's stock, valued at approximately $20,235,000. Abbott Laboratories accounts for 0.6% of Fidelity National Financial Inc.'s investment portfolio, making the stock its 13th largest position.

A number of other hedge funds also recently bought and sold shares of the business. BlackRock Inc. increased its stake in shares of Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the period. State Street Corp boosted its holdings in Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares in the last quarter. Capital International Investors boosted its holdings in Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock valued at $7,922,519,000 after acquiring an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP increased its position in Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors raised its holdings in Abbott Laboratories by 1.0% in the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker's stock worth $4,907,523,000 after purchasing an additional 400,400 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ABT. Bank of America cut their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Piper Sandler restated an "overweight" rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. TD Cowen lifted their price objective on Abbott Laboratories from $115.00 to $135.00 and gave the company a "buy" rating in a research report on Tuesday. Weiss Ratings raised Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of "Moderate Buy" and an average target price of $119.50.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott's next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Abbott Laboratories Price Performance

Shares of ABT opened at $112.63 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The firm's 50-day simple moving average is $102.61 and its two-hundred day simple moving average is $100.22. The stock has a market cap of $194.89 billion, a PE ratio of 36.45, a price-to-earnings-growth ratio of 2.16 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business's revenue was up 13.0% on a year-over-year basis. During the same period last year, the business earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories's payout ratio is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source